+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

TAVR Embolic Protection Market By Product: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 140 Pages
  • October 2023
  • Region: Global
  • Allied Market Research
  • ID: 5916331
The TAVR embolic protection market was valued for $108,782.53 thousand in 2022 and is estimated to reach $405,440.67 thousand by 2032, exhibiting a CAGR of 14% from 2023 to 2032.

Transcatheter aortic valve replacement (TAVR) embolic protection devices are specialized medical devices used during TAVR procedures. TAVR is a minimally invasive surgical technique designed to treat aortic valve stenosis, a condition in which the aortic valve in the heart becomes narrowed and obstructs blood flow. During TAVR, a new artificial valve is typically inserted into the heart through a catheter, avoiding the need for open-heart surgery.

Embolic protection devices used in TAVR procedures are specifically designed to capture and prevent the release of embolic debris (small particles or clots) that may break loose during the procedure. These embolic debris can potentially travel through the bloodstream and cause blockages or damage to other organs, including the brain, which can lead to complications such as stroke or organ damage.

The primary function of TAVR embolic protection devices is to reduce the risk of embolic events by capturing and containing any debris that might dislodge during the valve replacement procedure. These devices often consist of filters or mesh-like structures that are inserted into blood vessels to catch and trap any embolic material before it can cause harm. The growth of the TAVR embolic protection market is primarily driven by rise in incidence of cardiovascular diseases, particularly aortic valve stenosis, and the expanding geriatric population.

For instance, according to an article published in the National Library of Medicine, in 2021, aortic valve stenosis (AVS) is a common heart valve condition that becomes more prevalent with age, affecting approximately 13.2% of patients aged 75 and older. This condition is characterized by the scarring and accumulation of calcium in the valve cusp.

The growing prevalence of aortic valve stenosis in the elderly population, who often choose minimally invasive procedures such as TAVR, is a key factor driving the demand for cerebral embolic protection devices. These devices are essential for minimizing complications associated with the dislodgment of embolic debris during TAVR procedures. Thus, rise in preference for TAVR as a treatment option for aortic valve stenosis among elderly patients, who are more susceptible to cardiovascular diseases, fuels the demand for cerebral embolic protection devices and thereby drives the market growth.

However, factors that hamper the market growth include procedural complexities and high costs TAVR embolic protection devices. Utilization of these devices often requires specialized training for healthcare professionals, contributing to the challenge of implementation. In addition, the high cost associated with cerebral embolic protection devices can be a significant deterrent, particularly in regions with limited healthcare budgets.

Thus, the combination of these factors can hinder widespread adoption and market growth, necessitating efforts to simplify procedures and reduce costs to make these devices more accessible to healthcare providers and patients. Furthermore, the market is poised for potential growth, owing to a rise in initiatives undertaken by government organizations and key industry players in the development of advanced devices. These collaborative efforts aim to enhance the safety and effectiveness of cerebral embolic protection devices, which can lead to better patient outcomes.

In addition, ongoing clinical trials focused on improving these devices are expected to yield promising results. These developments are anticipated to create lucrative opportunities for the market expansion during the forecast period, as they can lead to the introduction of more innovative and efficient cerebral embolic protection solutions, meeting the evolving needs of healthcare providers and patients.

The TAVR embolic protection market is segmented into product type and region. By product type, the market is categorized into SENTINEL cerebral protection system and TriGUARD 3 CEP device technology. Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The key players operating in the TAVR embolic protection market are Boston Scientific Corporation, Edward Lifesciences Corporation, Filterlex Medical Ltd., Innovative Cardiovascular Solutions, LLC., Protembis GmbH, Transverse Medical Inc., Emboline, Inc., Cardioptimus ,EnCompass Technologies, Inc., and Venus MedTech HangZhou Inc. The key players have adopted strategies such as product approval, funding and clinical trials to enhance their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tavr embolic protection market analysis from 2022 to 2032 to identify the prevailing tavr embolic protection market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tavr embolic protection market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tavr embolic protection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Product

  • SENTINEL cerebral protection system
  • TriGUARD 3 CEP device technology

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East And Africa
  • Key Market Players
  • Protembis GmbH
  • Innovative Cardiovascular Solutions, LLC.
  • Filterlex Medical Ltd.
  • Cardioptimus
  • Transverse Medical Inc.
  • Venus MedTech HangZhou Inc.
  • EnCompass Technologies, Inc.
  • Boston Scientific Corporation
  • Edward Lifesciences Corporation
  • Emboline, Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.3. Porter’s five forces analysis
3.4. Market dynamics
CHAPTER 4: TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT
4.1. Overview
4.2. SENTINEL cerebral protection system
4.3. TriGUARD 3 CEP device technology
CHAPTER 5: TAVR EMBOLIC PROTECTION MARKET, BY REGION
5.1. Overview
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. LAMEA
CHAPTER 6: COMPETITIVE LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product mapping of top 10 player
6.4. Competitive dashboard
6.5. Competitive heatmap
6.6. Top player positioning, 2022
CHAPTER 7: COMPANY PROFILES
7.1. Boston Scientific Corporation
7.2. Edward Lifesciences Corporation
7.3. Filterlex Medical Ltd.
7.4. Protembis GmbH
7.5. Innovative Cardiovascular Solutions, LLC.
7.6. EnCompass Technologies, Inc.
7.7. Transverse Medical Inc.
7.8. Emboline, Inc.
7.9. Cardioptimus
7.10. Venus MedTech HangZhou Inc.
List of Tables
Table 01. Global Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 02. Tavr Embolic Protection Market for Sentinel Cerebral Protection System, by Region, 2022-2032 ($Thousand)
Table 03. Tavr Embolic Protection Market for Triguard 3 Cep Device Technology, by Region, 2022-2032 ($Thousand)
Table 04. Tavr Embolic Protection Market, by Region, 2022-2032 ($Thousand)
Table 05. North America Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 06. North America Tavr Embolic Protection Market, by Country, 2022-2032 ($Thousand)
Table 07. U.S. Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 08. Canada Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 09. Europe Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 10. Europe Tavr Embolic Protection Market, by Country, 2022-2032 ($Thousand)
Table 11. Germany Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 12. France Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 13. UK Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 14. Italy Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 15. Rest of Europe Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 16. Asia-Pacific Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 17. Asia-Pacific Tavr Embolic Protection Market, by Country, 2022-2032 ($Thousand)
Table 18. Japan Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 19. China Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 20. India Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 21. Australia Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 22. Rest of Asia-Pacific Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 23. LAMEA Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 24. LAMEA Tavr Embolic Protection Market, by Country, 2022-2032 ($Thousand)
Table 25. Latin America Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 26. Middle East and Africa Tavr Embolic Protection Market, by Product, 2022-2032 ($Thousand)
Table 27. Boston Scientific Corporation: Key Executives
Table 28. Boston Scientific Corporation: Company Snapshot
Table 29. Boston Scientific Corporation: Product Segments
Table 30. Boston Scientific Corporation: Product Portfolio
Table 31. Edward Lifesciences Corporation: Key Executives
Table 32. Edward Lifesciences Corporation: Company Snapshot
Table 33. Edward Lifesciences Corporation: Product Segments
Table 34. Edward Lifesciences Corporation: Product Portfolio
Table 35. Filterlex Medical Ltd.: Key Executives
Table 36. Filterlex Medical Ltd.: Company Snapshot
Table 37. Filterlex Medical Ltd.: Product Segments
Table 38. Filterlex Medical Ltd.: Product Portfolio
Table 39. Filterlex Medical Ltd.: Key Stratergies
Table 40. Protembis Gmbh: Key Executives
Table 41. Protembis Gmbh: Company Snapshot
Table 42. Protembis Gmbh: Product Segments
Table 43. Protembis Gmbh: Product Portfolio
Table 44. Protembis Gmbh: Key Stratergies
Table 45. Innovative Cardiovascular Solutions, LLC.: Key Executives
Table 46. Innovative Cardiovascular Solutions, LLC.: Company Snapshot
Table 47. Innovative Cardiovascular Solutions, LLC.: Product Segments
Table 48. Innovative Cardiovascular Solutions, LLC.: Product Portfolio
Table 49. Encompass Technologies, Inc.: Key Executives
Table 50. Encompass Technologies, Inc.: Company Snapshot
Table 51. Encompass Technologies, Inc.: Product Segments
Table 52. Encompass Technologies, Inc.: Product Portfolio
Table 53. Encompass Technologies, Inc.: Key Stratergies
Table 54. Transverse Medical Inc.: Key Executives
Table 55. Transverse Medical Inc.: Company Snapshot
Table 56. Transverse Medical Inc.: Product Segments
Table 57. Transverse Medical Inc.: Product Portfolio
Table 58. Emboline, Inc.: Key Executives
Table 59. Emboline, Inc.: Company Snapshot
Table 60. Emboline, Inc.: Product Segments
Table 61. Emboline, Inc.: Product Portfolio
Table 62. Emboline, Inc.: Key Stratergies
Table 63. Cardioptimus: Key Executives
Table 64. Cardioptimus: Company Snapshot
Table 65. Cardioptimus: Product Segments
Table 66. Cardioptimus: Product Portfolio
Table 67. Venus Medtech Hangzhou Inc.: Key Executives
Table 68. Venus Medtech Hangzhou Inc.: Company Snapshot
Table 69. Venus Medtech Hangzhou Inc.: Product Segments
Table 70. Venus Medtech Hangzhou Inc.: Product Portfolio
Table 71. Venus Medtech Hangzhou Inc.: Key Stratergies
List of Figures
Figure 01. Tavr Embolic Protection Market, 2022-2032
Figure 02. Segmentation of Tavr Embolic Protection Market, 2022-2032
Figure 03. Top Impacting Factors in Tavr Embolic Protection Market (2022 to 2032)
Figure 04. Top Investment Pockets in Tavr Embolic Protection Market (2023-2032)
Figure 05. Low Bargaining Power of Suppliers
Figure 06. Moderate Threat of New Entrants
Figure 07. Moderate Threat of Substitutes
Figure 08. Moderate Intensity of Rivalry
Figure 09. Moderate Bargaining Power of Buyers
Figure 10. Global Tavr Embolic Protection Market: Drivers, Restraints and Opportunities
Figure 11. Tavr Embolic Protection Market, by Product, 2022 and 2032 (%)
Figure 12. Comparative Share Analysis of Tavr Embolic Protection Market for Sentinel Cerebral Protection System, by Country 2022 and 2032 (%)
Figure 13. Comparative Share Analysis of Tavr Embolic Protection Market for Triguard 3 Cep Device Technology, by Country 2022 and 2032 (%)
Figure 14. Tavr Embolic Protection Market by Region, 2022 and 2032 (%)
Figure 15. U.S. Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 16. Canada Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 17. Germany Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 18. France Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 19. UK Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 20. Italy Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 21. Rest of Europe Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 22. Japan Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 23. China Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 24. India Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 25. Australia Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 26. Rest of Asia-Pacific Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 27. Latin America Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 28. Middle East and Africa Tavr Embolic Protection Market, 2022-2032 ($Thousand)
Figure 29. Top Winning Strategies, by Year (2020-2023)
Figure 30. Top Winning Strategies, by Development (2020-2023)
Figure 31. Top Winning Strategies, by Company (2020-2023)
Figure 32. Product Mapping of Top 10 Players
Figure 33. Competitive Dashboard
Figure 34. Competitive Heatmap: Tavr Embolic Protection Market
Figure 35. Top Player Positioning, 2022
Figure 36. Boston Scientific Corporation: Net Sales, 2020-2022 ($ Million)
Figure 37. Boston Scientific Corporation: Revenue Share by Segment, 2022 (%)
Figure 38. Boston Scientific Corporation: Revenue Share by Region, 2022 (%)
Figure 39. Edward Lifesciences Corporation: Net Sales, 2020-2022 ($ Million)
Figure 40. Edward Lifesciences Corporation: Revenue Share by Segment, 2022 (%)
Figure 41. Edward Lifesciences Corporation: Revenue Share by Region, 2022 (%)

Executive Summary

According to the report, the tavr embolic protection market was valued at $108.8 million in 2022, and is estimated to reach $405.4 million by 2032, growing at a CAGR of 14% from 2023 to 2032.

The TAVR embolic protection market is likely to experience a significant growth rate of 14% from 2023-2032 owing to increasing market demand of SENTINEL Cerebral Protection System segment.

Transcatheter Aortic Valve Replacement (TAVR) embolic protection devices are specialized medical tools designed to safeguard patients undergoing TAVR procedures from the risk of embolic complications. During TAVR, a prosthetic aortic valve is implanted through a catheter, which can dislodge debris and small particles that may enter the bloodstream, potentially causing strokes or other adverse events. Embolic protection devices act as filters or shields, intercepting and capturing these particles, preventing their passage to vital organs such as the brain. These devices enhance the safety and efficacy of TAVR, minimizing the risk of embolic events and contributing to better patient outcomes in the treatment of aortic valve stenosis.

The aging population is exerting a significant influence on the growth of the embolic protection device market. As the global demographic landscape shifts towards an increasingly elderly population, the prevalence of cardiovascular diseases, including aortic stenosis, is on the rise. This demographic segment is more susceptible to such health conditions, necessitating interventions like Transcatheter Aortic Valve Replacement (TAVR), where embolic protection devices play a crucial role. The surge in elderly patients opting for minimally invasive procedures like TAVR to address their cardiovascular issues amplifies the demand for these devices, making the aging population a driving force behind the sustained growth of the embolic protection device market.

Furthermore, technological advancements are playing a pivotal role in propelling market growth. Continuous innovation has led to the development of more sophisticated and efficient embolic protection devices. These devices now offer improved filter designs, materials, deployment techniques, and enhanced navigability within the cardiovascular system, making them increasingly attractive to healthcare providers and patients alike. For instance, EnCompass Technologies, Inc., a privately held medical device company, has developed F2 filter, which has the smallest average pore size among all CEP devices at 30 µm. Moreover, During the TAVR procedure, 360-degree wall apposition of the F2 filter in the aortic arch is designed to prevent migration.

In addition, cardiologists and healthcare professionals are increasingly recognizing the value of cerebral embolic protection devices. As awareness of the potential risks of embolic events during TAVR procedures grows, cardiologists are more inclined to incorporate these devices into their practice. This adoption trend is bolstered by clinical evidence showcasing their effectiveness in reducing the risk of stroke and other complications during TAVR interventions. For instance, the research published in the new England journal of medicine, in 2022, demonstrated that out of 3000 randomized patients, 1501 were assigned to the CEP (cerebral embolic protection) group and 1499 to the control group, where it was recorded that incidence of stroke within 72 hours after TAVR or before discharge was 2.3% in CEP group and 2.9 % in control group. This study's findings highlight the impact on incidence of periprocedural stroke. Thereby driving the demand for cerebral embolic protection device adoption.

Furthermore, the rise in regulatory approvals is further contributing to the market growth. For instance, in March 2020, Keystone Heart Ltd., a Venus Medtech Company, received European CE Mark for the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. The device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and other transcatheter heart procedures. Such approvals not only enhance patient safety but also instill confidence among healthcare providers, thereby driving the adoption and market growth of these critical medical devices.

The global TAVR embolic protection market is segmented into product type and region. By product type, the market is categorized into SENTINEL Cerebral Protection System and TriGUARD 3 CEP Device Technology. Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, the UK, Italy and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The report provides a comprehensive analysis of the key players that operate in the global TAVR embolic protection market such Boston Scientific Corporation, Edward Lifesciences Corporation, Filterlex Medical Ltd., Innovative Cardiovascular Solutions, LLC., Protembis GmbH,Transverse Medical Inc., Emboline, Inc., Cardioptimus,EnCompass Technologies, Inc., and Venus MedTech HangZhou Inc. Key players operating in the market have adopted product approval, funding and clinical trials as their key strategies to expand their product portfolio.

Key Market Insights

  • On the basis of product type, the SENTINEL Cerebral Protection System segment held the largest market share in 2022. However, the TriGUARD 3 CEP Device Technology segment is anticipated to grow at the fastest CAGR during the forecast period.
  • Region-wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • Protembis GmbH
  • Innovative Cardiovascular Solutions, LLC.
  • Filterlex Medical Ltd.
  • Cardioptimus
  • Transverse Medical Inc.
  • Venus MedTech HangZhou Inc.
  • EnCompass Technologies, Inc.
  • Boston Scientific Corporation
  • Edward Lifesciences Corporation
  • Emboline, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...